These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 16390597)
1. Overview of drug therapy for multiple myeloma. Saunders G J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597 [TBL] [Abstract][Full Text] [Related]
2. New treatments for multiple myeloma. Richardson PG; Schlossman R; Hideshima T; Anderson KC Oncology (Williston Park); 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7. PubMed ID: 16506632 [TBL] [Abstract][Full Text] [Related]
3. The emerging role of arsenic trioxide as an immunomodulatory agent in the management of multiple myeloma. Kalmadi SR; Hussein MA Acta Haematol; 2006; 116(1):1-7. PubMed ID: 16809883 [TBL] [Abstract][Full Text] [Related]
8. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778 [TBL] [Abstract][Full Text] [Related]
9. New drugs for myeloma. Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058 [TBL] [Abstract][Full Text] [Related]
10. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. Chanan-Khan AA; San Miguel JF; Jagannath S; Ludwig H; Dimopoulos MA Clin Cancer Res; 2012 Apr; 18(8):2145-63. PubMed ID: 22328563 [TBL] [Abstract][Full Text] [Related]
12. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
16. New developments in the treatment of patients with multiple myeloma. Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818 [TBL] [Abstract][Full Text] [Related]
17. Pomalidomide in the treatment of relapsed multiple myeloma. Forsberg PA; Mark TM Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756 [TBL] [Abstract][Full Text] [Related]
18. The emerging role of novel therapies for the treatment of relapsed myeloma. Richardson PG; Hideshima T; Mitsiades C; Anderson KC J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684 [TBL] [Abstract][Full Text] [Related]
19. Evolving role of novel agents for maintenance therapy in myeloma. Magarotto V; Palumbo A Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169 [TBL] [Abstract][Full Text] [Related]
20. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]